Geographic Variation in Cardioprotective Antihypertensive Medication Usage in Dialysis Patients

Department of Medicine, Division of Nephrology and Hypertension, University of Kansas School of Medicine, Kansas City, KS 66160, USA.
American Journal of Kidney Diseases (Impact Factor: 5.76). 07/2011; 58(1):73-83. DOI: 10.1053/j.ajkd.2011.02.387
Source: PubMed

ABSTRACT Despite their high risk of adverse cardiac outcomes, persons on long-term dialysis therapy have had lower use of antihypertensive medications with cardioprotective properties, such as angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), β-blockers, and calcium channel blockers, than might be expected. We constructed a novel database that permits detailed exploration into the demographic, clinical, and geographic factors associated with the use of these agents in hypertensive long-term dialysis patients.
National cross-sectional retrospective analysis linking Medicaid prescription drug claims with US Renal Data System core data.
48,882 hypertensive long-term dialysis patients who were dually eligible for Medicaid and Medicare services in 2005.
Demographics, comorbid conditions, functional status, and state of residence.
Prevalence of cardioprotective antihypertensive agents in Medicaid pharmacy claims and state-specific observed to expected ORs of medication exposure.
Factors associated with medication use were modeled using multilevel logistic regression models.
In multivariable analyses, cardioprotective antihypertensive medication exposure was associated significantly with younger age, female sex, nonwhite race, intact functional status, and use of in-center hemodialysis. Diabetes was associated with a statistically significant 28% higher odds of ACE-inhibitor/ARB use, but congestive heart failure was associated with only a 9% increase in the odds of β-blocker use and no increase in ACE-inhibitor/ARB use. There was substantial state-by-state variation in the use of all classes of agents, with a greater than 2.9-fold difference in adjusted-rate ORs between the highest and lowest prescribing states for ACE inhibitors/ARBs and a 3.6-fold difference for β-blockers.
Limited generalizability beyond study population.
In publicly insured long-term dialysis patients with hypertension, there were marked differences in use rates by state, potentially due in part to differences in Medicaid benefits. However, geographic characteristics also were associated with exposure, suggesting clinical uncertainty about the utility of these medications.

Download full-text


Available from: Purna Mukhopadhyay, Apr 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Geographic variation in the occurrence and outcomes of chronic kidney disease (CKD) is major area of study in epidemiology and health services and outcomes research. Geographic attributes may be as diverse as the physical, socioeconomic, and medical care characteristics of an environment. This review summarizes the recent literature pertaining to geographic risk factors and CKD. Studies have reported on the association between CKD and physical attributes of place (ambient temperature and altitude), the impact of disasters on CKD populations, new diseases characterized by regional localization, national variations in CKD incidence and prevalence, regional variation in end-stage renal disease incidence, residential mobility and CKD risk factors, and geographic variations in CKD care. The emerging role of tools for geospatial studies - including multilevel analytical designs, which reduce the likelihood of an ecologically biased inference, and geographic information systems, which allow the simultaneous linkage, analysis, and mapping of geospatial data - is illustrated by these studies. Our understanding of the occurrence and outcomes of CKD will continue to be expanded and deepened by the explicit study of attributes associated with place as a potential risk factor. Many of the studies reviewed are largely hypothesis generating, and a better understanding of the role of geography in the study of CKD awaits investigations that probe the mechanisms that link attributes of place to disease processes.
    Current opinion in nephrology and hypertension 03/2012; 21(3):323-8. DOI:10.1097/MNH.0b013e3283521dae · 3.96 Impact Factor
  • Journal of diabetes and its complications 06/2012; 26(4):255-6. DOI:10.1016/j.jdiacomp.2012.05.004 · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite uncertainty about their effectiveness in chronic dialysis patients, statin use has increased in recent years. Little is known about the demographic, clinical, and geographic factors associated with statin exposure in end-stage renal disease (ESRD) patients. To analyze the demographic, clinical, and geographic factors associated with use of statins among chronic dialysis patients. Cross-sectional analysis. Prevalent dialysis patients across the U.S. 55,573 chronic dialysis patients who were dually eligible for Medicaid and Medicare services during the last four months of 2005. Using Medicaid prescription drug claims and United States Renal Data System core data, we examined demographics, comorbid conditions, and state of residence using hierarchical logistic regression models to determine their associations with statin use. Prescription for a statin. Factors associated with a prescription for a statin. Statin exposure was significantly associated with older age, female sex, Caucasian (versus African-American) race, body mass index, use of self-care dialysis, diabetes, and comorbidity burden. Moreover, there was substantial state-by-state variation in statin use, with a greater than 2.3-fold difference in adjusted odds ratios between the highest- and lowest-prescribing states. Among publicly insured chronic dialysis patients, there were marked differences between states in the use of HMG-CoA reductase inhibitors above and beyond patient characteristics. This suggests substantial clinical uncertainty about the utility of these medications. Understanding how such regional variations impact patient care in this high-risk population is an important focus for future work.
    Journal of General Internal Medicine 06/2012; 27(11):1475-83. DOI:10.1007/s11606-012-2112-7 · 3.42 Impact Factor
Show more